Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shengruling
- Development stage
- Phase 2
- Lead developer
- Xi'an Zhouliang Mingkang Biopharmaceutical Technology
- Administration
- Oral
01
Overview
Shengruling is a Traditional Chinese Medicine (TCM) capsule developed by Xi'an Zhouliang Mingkang Biopharmaceutical Technology Co., Ltd. for the treatment of breast hyperplasia. It is specifically indicated for patients presenting with the TCM syndrome of liver depression and phlegm coagulation. The drug's efficacy is measured by improvements in breast pain, reduction in the size of breast lumps, and overall improvement in TCM symptoms. It has undergone Phase II clinical testing in China to evaluate its safety and optimal dosage.
- Brand names
- Shengruling
- Other names
- Shengruling CapsuleShengruling Jiaonang
Beyond the preview
Go deeper on Shengruling.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shengruling.